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Abstract
Astrocytic brain tumors are the most frequent primary brain tumors. Treatment with radio-
and chemotherapy has increased survival making prognostic biomarkers increasingly
important. The aim of the present study was to investigate the expression and prognostic
value of transferrin receptor-1 (TfR1) as well as ferritin heavy (FTH) and light (FTL) chain in
astrocytic brain tumors. A cohort of 111 astrocytic brain tumors (grade II-IV) was stained
immunohistochemically with antibodies against TfR1, FTH, and FTL and scored semi-quan-
titatively. Double-immunofluorescence stainings were established to determine the pheno-
type of cells expressing these markers. We found that TfR1, FTH, and FTL were expressed
by tumor cells in all grades. TfR1 increased with grade (p<0.001), but was not associated
with prognosis in the individual grades. FTH and FTL were expressed by tumor cells and
cells with microglial/macrophage morphology. Neither FTH nor FTL increased with malig-
nancy grade, but low FTH expression by both tumor cells (p = 0.03) and microglia/macro-
phages (p = 0.01) correlated with shorter survival in patients anaplastic astrocytoma. FTL-
positive microglia/macrophages were frequent in glioblastomas, and high FTL levels corre-
lated with shorter survival in the whole cohort (p = 0.01) and in patients with anaplastic astro-
cytoma (p = 0.02). Double-immunofluorescence showed that TfR1, FTH, and FTL were co-
expressed to a limited extent with the stem cell-related marker CD133. FTH and FTL were
also co-expressed by IBA-1-positive microglia/macrophages. In conclusion, TfR1 was
highly expressed in glioblastomas and associated with shorter survival in the whole cohort,
but not in the individual malignancy grades. Low levels of FTH-positive tumor cells and
microglia/macrophages were associated with poor survival in anaplastic astrocytomas,
while high amounts of FTL-positive microglia/macrophages had a negative prognostic
value. The results suggest that regulation of the iron metabolism in astrocytic brain tumors is
complex involving both autocrine and paracrine signaling.
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Introduction
Astrocytic brain tumors are the most frequent and aggressive brain tumors in adults [1]. The
most common and aggressive type is the glioblastoma (GBM) having a median survival of 15
months [2, 3]. High-dose radiotherapy and temozolomide have increased survival [2, 3] mak-
ing prognostic biomarkers in gliomas increasingly important. Tumor cells in GBM display a
cellular hierarchy with brain tumor-initiating cells (BTIC) at the apex [4, 5]. BTIC are located
in niches and thrive in stressful conditions such as hypoxia, inflammation, oxidative stress,
and low supply of glucose [6–10]. Iron metabolism is thought to be involved in mechanisms
supporting these conditions [11–13]. Deregulation of the iron homeostasis has also been
linked to other cancers as well as neuro-degenerative diseases [14].
Iron is an important co-factor required for biological activity of many enzymes, and the
iron metabolism is strictly controlled to avoid free iron toxicity [15]. Iron enters the brain
across the blood-brain-barrier, and uptake in the capillary endothelial cells is regulated by
transferrin receptor-1 (TfR1) [16]. A similar regulation has been reported in cancer cells [17].
Intracellular iron is stored by two subtypes of the protein ferritin that differ in their subunits,
either ferritin heavy (FTH) or light (FTL) chain [18]. FTH is important for rapid uptake and
reutilization of iron, while FTL is associated with long-term storage [19].
High expression of TfR1 has been observed in different cancers including breast, lung, and
bladder cancer as well as in malignant gliomas [17]. In The Cancer Genome Atlas (TCGA)
dataset, a negative correlation was found between overall survival and high mRNA levels of
TfR1, FTL, and FTH in gliomas. Recently, similar results were obtained when the three iron-
related proteins were investigated on tissue microarrays (TMAs) containing tissue from 95
gliomas of oligodendroglial and astrocytic subtype [20]. Supporting BTIC functions, TfR1-po-
sitive GBM cells formed tumorspheres more frequently than TfR1-negative cells in vitro.
Moreover, in vivo xenografting showed that mice implanted with TfR1high GBM cells devel-
oped tumors earlier than mice implanted with TfR1low GBM cells [20]. BTICs sorted based on
the expression of CD133 showed elevated levels of TfR1, FTH, and FTL compared to non-
BTICs. When short hairpin RNA interference was used to ablate ferritin activity, decreased
BTIC proliferation was observed. Further, implanting BTICs in mice containing FTH or FTL
knockdown resulted in sparse or absent tumor formation [20].
The aim of the present study was to investigate the expression and prognostic value of
TfR1, FTL, and FTH in a patient cohort of 111 astrocytomas. Immunohistochemical staining
was performed on whole slides as expression of BTIC-related markers may be under- or over-
estimated in TMAs due to the heterogeneity of gliomas [21]. Also, a possible expression of
FTL and FTH by microglia/macrophages could be taken more comprehensively into account.
In addition, we wanted to investigate the prognostic potential of TfR1, FTL, and FTH in indi-
vidual glioma grades, since this aspect is of high clinical interest. To determine the phenotype
of TfR1-, FTL-, and FTH-positive cells, a panel of double-immunofluorescence stainings was
established consisting of the BTIC-related markers CD133 [22, 23] and nestin [24–26], the
astrocytic marker glial fibrillary acidic protein (GFAP), and the microglial/macrophage
marker ionized calcium-binding adapter molecule 1 (IBA-1).
Material and methods
Odense University Hospital (OUH) astrocytoma cohort
The tumor tissue samples (n = 111) were obtained from patients diagnosed with primary
astrocytoma and included 70 GBMs (World Health Organization (WHO) grade IV), 18 ana-
plastic astrocytomas (AAs) (WHO grade III), and 23 diffuse astrocytomas (DAs) (WHO grade
Iron-related proteins in astrocytomas
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II). All patients underwent initial surgery between 1994 and 2005 at OUH, Denmark. None of
the patients received treatment prior to the surgery. To ensure a sufficient and representative
amount of high quality viable tumor tissue, we excluded: tumor tissue removed by ultrasonic
aspiration, gliomas where all the material had been frozen before paraffin embedding, and
biopsies where the material measured less than 4 mm. The tumors were re-evaluated by two
independent neuropathologists according to the WHO guidelines 2007 [27]. Patient character-
istics are presented in Table 1.
Tissue
Fresh tissue biopsies were fixed in 4% neutral buffered formaldehyde and paraffin embedded.
Three μm sections were cut on a microtome and stained routinely with haematoxylin-eosin to
define representative tumor regions.
Normal brain tissue specimens for staining controls were obtained from two adult autop-
sies. Cause of death was not related to any CNS diseases. The tissue was fixed in 4% neutral
buffered formaldehyde for 24 hours.
The official Danish ethical review board named the Regional Scientific Ethical Committee
of the Region of Southern Denmark approved the use of human glioma tissue (permission J.
No. S-2011 0022). Use of the tissue was not prohibited by any of the patients according to the
Danish Tissue Application Register.
Immunohistochemistry
Three μm paraffin sections were stained on a Dako Autostainer Universal Staining System
(Dako, Glostrup, Denmark). The sections were deparaffinized, and heat induced epitope
retrieval (HIER) was performed by incubation in a buffer solution consisting of 10 mmol/L
Tris-base and 0.5 mmol/L EGTA, pH 9. After blocking of endogenous peroxidase activity by
incubation in 1.5% hydrogen peroxide, the sections were incubated for 60 min with primary
antibodies against TfR1 (CD71) (10F11, 1+50, NovoCastra, Newcastle, United Kingdom),
FTH (ab65080, 1+800, Abcam, Cambridge, United Kingdom), or FTL (ab69090, 1+1000,
Abcam). The antigen-antibody complex was detected using EnVision (Dako). Visualization
was performed using DAB (diaminobenzidine) as chromogen. Finally, sections were counter-
stained with Mayer’s hematoxylin, and coverslips were mounted with Aquatex. Paraffin
sections from a TMA containing 28 normal tissues and 12 cancers were used as controls.
Omitting primary antibodies served as negative controls as well as controls for non-specific
staining related to the detection system.
Table 1. Clinicopathological characteristics of patient samples.
All astrocytomas DA AA GBM
Patients (n) 111 23 18 70
OS (months)
Median 10.5 55.5 18.4 8.4
Range (0.07–241.3) (2.1–241.3) (2.2–110.1) (0.07–153.4)
Age (years)
Median 58 45 57 61
Range (2–78) (2–75) (14–77) (21–78)
Sex (male/female) 70/41 15/8 11/7 44/26
Endpoint (alive/dead) 6/105 5/18 0/18 1/69
Abbreviations: AA anaplastic astrocytoma, DA diffuse astrocytoma, GBM glioblastoma, OS overall survival.
https://doi.org/10.1371/journal.pone.0182954.t001
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Double-immunofluorescence
Double-immunofluorescence stainings were performed on a TMA containing tissue from
nine GBMs, normal colon, placenta, cerebellum, and rat hippocampus as previously described
[20, 28, 29]. The preparations as well as the first step in the stainings were as described above.
After detection of TfR1 (CD71) (1+200), FTH (1+12000), or FTL (1+16000) using Catalyzed
Signal Amplification II kit with FITC (CSA II, Dako), a second round of HIER followed by
quenching of endogen peroxidase was performed. Sections were then incubated with anti-
bodies against nestin (96908, 1+200, R&D systems, Minneapolis, Minnesota, USA), CD133
(W6B3C1, 1+40, Miltenyi Biotec, Teterow, Germany), GFAP (Z0334, 1+8000, Dako), or IBA-
1 (019–19741 1+12000, Wako Pure Chemical Industries, Osaka, Japan). Tyramide Amplifica-
tion Signal Cyanine 5 (TSA-Cy5, Perkin Elmer, Waltham, Massachusetts, USA) was used as
detection system. Sections were mounted with VECTASHIELD Antifade Mounting Medium
with 4.6-diamidino-2-phenylindole (DAPI, VWR International, Radnor, Pennsylvania, USA).
Fluorescent images were taken with a Leica DM6000B microscope connected to an Olympus
DP72 1.4 Mega Pixel CCD (Olympus, Tokyo, Japan) camera using DAPI (Omega XF06,
Omega Optical, Brattleboro, Vermont, USA), FITC (Leica, Wetzlar, Germany) and Cy5
(Omega XF110-2) filters.
Pathological scoring
The immunohistochemical stainings were assessed using semi-quantitative scoring on whole
slides. Prior to scoring of the whole cohort, ten tumors were evaluated and scored repeatedly
to ensure reproducibility. Before the scoring was performed, a set of criteria was established
and carefully followed (Table 2). For each individual staining, two parameters, “tumor cell
fraction” and “tumor cell intensity”, were assessed and given a score from 0–2 with 0 indicat-
ing negative staining, 1 moderate staining, and 2 strong staining. The parameter “tumor cell
score” was defined as a sum of the tumor cell fraction score and tumor cell intensity score with
a maximum score of 4. In the ferritin stainings, positive cells with microglial/macrophage
Table 2. Pathological scoring of TfR1, FTH, and FTL.
TfR1 score 0 1 2
Positive tumor cell fraction 0% to <2% 2% to < 75% 75% to 100%
Tumor cell intensity None Faint Intense
FTH score 0 1 2
Positive tumor cell fraction 0% to <2% 2% to < 75% 75% to 100%
Tumor cell intensity None Faint Intense
Positive microglial fraction 0% to <2% 2% to < 75% 75% to 100%
Microglial intensity None Faint Intense
FTL score 0 1 2
Positive tumor cell fraction 0% to <2% 2% to < 75% 75% to 100%
Tumor cell intensity None Faint Intense
Positive microglial fraction 0% to <2% 2% to < 75% 75% to 100%
Microglial intensity None Faint Intense
For each tumor, a tumor cell score for TfR1, FTH, and FTL was calculated by adding up the two tumor
scores: positive tumor cell fraction and tumor cell intensity, resulting in a maximum score of 4. Similarly, a
microglial score for FTH and FTL was calculated by adding up the two microglial scores: positive microglial
fraction and microglial intensity resulting in a maximum score of 4.
Abbreviations: FTH ferritin heavy chain, FTL ferritin light chain, TfR1 transferrin receptor-1.
https://doi.org/10.1371/journal.pone.0182954.t002
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morphology were observed, and two additional parameters were therefore scored: “microglial
fraction” and “microglial intensity”. The parameter “microglial score” was defined as a sum of
the microglial fraction score and microglial intensity score with a maximum score of 4. Cells
with microglial/macrophage morphology were not incorporated into the tumor cell scores.
Necrotic areas and infiltration zones were not included in the assessment. Patient data are
available in S1 File.
In silico analyses of the Cancer Genome Atlas (TCGA)
TCGA gene expression datasets for TfR1 (TFRC), FTH (FTH1), FTL, and IBA-1 (AIF-1) were
exported from GlioVis (https://gliovis.bioinfo.cnio.es). Data were available for 497 patients
with primary GBM [30]. Datasets used in the present study are available in S2 File.
Statistical analysis
Tumor cell score and microglial score were compared with tumor grades using the non-
parametric Kruskal Wallis test followed by Dunn’s multiple comparisons test. Overall survival
was defined as time from primary surgery until death or date of censoring (April 10th, 2015).
The univariate relationships were illustrated by Kaplan-Meier plots, and differences in overall
survival were analyzed using Log Rank tests. This was performed for all WHO grades com-
bined and for DAs, AAs, and GBMs separately. Multivariate Cox proportional hazard regres-
sion analyses including age and sex were performed for GBMs. For survival analyses, patients
were grouped into two, based on the summed scores with score 0–2 representing the low
expression group and score 3–4 representing the high expression group. All assumptions were
tested, and all analyses were carried out in STATA (StataCorp LP, Bryan, Texas, USA).
Correlations between IBA-1 gene expression, GBM subtypes, and expression of the three
iron-related genes were investigated using the non-parametric Spearman’s correlation. Using
the TfR1, FTH, and FTL datasets, survival analyses were carried out for each GBM subtype
with the median as cutoff value.
Results
Staining in normal brain
In the subventricular zone TfR1-positive cells were observed in the ependymal layer (Fig 1A),
while few cells in and beneath the ependymal layer were FTH-positive (Fig 1B). The ependy-
mal cells did not express FTL, but a few cells beneath the ependymal expressed FTL (Fig 1C).
For TfR1, neurons in the neocortex had a weak expression (Fig 1D), and endothelium was
mainly positive stained in the small capillaries. For FTH, neurons in neocortex showed a mod-
erate expression, and the neuropil had a weak staining, while some cells morphologically
resembling microglia had a stronger staining (Fig 1E). A similar staining pattern was found
for FTL (Fig 1F).
Tumor cell staining in astrocytomas
In most DAs, TfR1 was not present (Fig 1G), while FTH and FTL expression patterns were
heterogeneous with strong, diffuse expression in some tumors and weak expression in others
(Fig 1H and Fig 1I). Likewise most AAs were TfR1-negative, but some expressed the protein
(Fig 2A), and FTH and FTL was heterogeneously expressed (Fig 2B and Fig 2C). GBM cells
were positive for TfR1 with a heterogeneous expression pattern containing regions of high
intensity with multiple positive tumor cells as well as regions without any TfR1-expressing
Iron-related proteins in astrocytomas
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cells. Multinucleated giant cells showed a weak TfR1 expression (Fig 2D), but had an intense
expression of FTH and especially FTL (Fig 2E and Fig 2F).
TfR1-positive tumor cells were often seen near blood vessels (Fig 2G), and in all tumors,
the endothelium of small blood vessels expressed TfR1 thereby serving as an internal positive
control. In contrast, blood vessels including glomeruloid vessels lacked expression of FTH (Fig
2H) and FTL (Fig 2I). Cells surrounding pseudo-palisading necrosis expressed TfR1 (Fig 2J),
FTH (Fig 2K) as well as FTL (Fig 2L).
In general, the expression patterns of FTH and FTL appeared very similar, although more
cells were positive for FTL, and the intensity of the positive cells was often stronger than that
of FTH-positive cells. The cells with the strongest FTL and FTH intensities resembled micro-
glia/macrophages exhibiting microstellate or macrophage morphology.
Fig 1. Normal brain tissue from subventricular zone and neocortex as well as DAs immunohistochemically stained with TfR1, FTH, and FTL.
Cells in the ependymal layer expressed TfR1 (A) and FTH (B). No expression of FTL (C) in the ependymal layer was seen. A few cells beneath the
ependymal layer were positive for FTH (B) and FTL (C) (arrows). In the neocortex, there was a weak TfR1 neuronal staining (D), but a stronger
neuronal staining for FTH (E) and FTL (F), which also stained the neuropil. In DAs, TfR1was mainly expressed by the endothelium (arrow) (G). The
FTH (H) and FTL (I) stainings were pronounced in many DAs with staining of both tumor cells (arrows) and microglia (arrowheads). Abbreviations: DA
diffuse astrocytoma, FTH ferritin heavy chain, FTL ferritin light chain, TfR1 transferrin receptor-1. Scale bar: 100 μm.
https://doi.org/10.1371/journal.pone.0182954.g001
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Association with grade and prognostic impact of tumor cell score in
astrocytomas
The TfR1 tumor cell score increased with malignancy grade (p<0.001) (Fig 3A). Neither FTH
(Fig 3B) nor FTL (Fig 3C) increased with grade.
When combining all grades, high TfR1 tumor cell score was associated with a poor progno-
sis (HR 2.5; 95% CI 1.59–3.79; p<0.001) (score 0–2: n = 74 and score 3–4: n = 39) (Fig 3D).
Differences in overall survival based on TfR1 expression could not be compared in DAs, since
all DAs received a low tumor cell score (Fig 3G). TfR1 tumor cell score was not associated
with overall survival in AAs (HR 1.2; 95% CI 0.27–5.69; p = 0.78) (score 0–2: n = 15 and score
Fig 2. AAs and GBMs immunohistochemically stained with TfR1, FTH, and FTL. AAs showed weak
TfR1staining (A) and stronger FTH (B) and FTL (C) staining. GBMs with giant cells were weakly positive for TfR1
(D), moderately positive for FTH (E), and strongly positive for FTL (F). GBMs had no or limited glomeruloid staining
for TfR1 (G), FTH (H), or FTL (I) (arrows). In GBMs with pseudo-palisading necroses (asterisks) TfR1-positive (J),
FTH-positive (K), and FTL-positive (L) cells were observed in perinecrotic areas. Cells with microglial/macrophage
morphology were easily identified in both the FTH (arrowheads) (E and K) and FTL stainings (arrowheads) (C and
L). Abbreviations: AA anaplastic astrocytoma, FTH ferritin heavy chain, FTL ferritin light chain, GBM glioblastoma,
TfR1 transferrin receptor-1. Scale bar: (A-I) 100 μm, (J-L) 100 μm.
https://doi.org/10.1371/journal.pone.0182954.g002
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3–4: n = 2) (Fig 3J) or in GBMs (HR 1.2; 95% CI 0.72–1.86; p = 0.55) (score 0–2: n = 35 and
score 3–4: n = 37) (Fig 3M). Multivariate analysis did not provide any additional information
for GBMs (Table 3).
Combining all astrocytomas, high FTH tumor cell score was associated with better outcome
(HR 0.6; 95% CI 0.37–0.87; p = 0.01) (score 0–2: n = 35 and score 3–4: n = 76) (Fig 3E). Only
one DA had a low FTH tumor cell score preventing statistical comparison (Fig 3H). In AAs, a
high FTH tumor cell score was associated with better outcome (HR 0.3; 95% CI 0.09–0.90;
p = 0.03) (score 0–2: n = 7 and score 3–4: n = 11) (Fig 3K). No association with overall survival
was observed in GBMs neither in univariate (HR 0.97; 95% CI: 0.60–1.59; p = 0.91) (score 0–2:
n = 35 and score 3–4: n = 37) (Fig 3N) nor in multivariate analysis (Table 3).
FTL tumor cell score was not associated with overall survival in all astrocytomas combined
(HR 1.0; 95% CI 0.67–1.56; p = 0.91) (score 0–2: n = 31 and score 3–4: n = 81) (Fig 3F), in
DAs (HR 1.1; 95% CI 0.39–3.12; p = 0.85) (score 0–2: n = 6 and score 3–4: n = 17) (Fig 3I), or
in AAs (HR 0.7; 95% CI 0.22–2.25; p = 0.55) (score 0–2: n = 4 and score 3–4: n = 14) (Fig 3L).
In GBMs, FTL did not correlate with survival, however, the subgroup of patients with low FTL
tumor cell score tended to have a better prognosis (HR 1.4; 95% CI 0.84–2.43; p = 0.19) (score
0–2: n = 21 and score 3–4: n = 49) (Fig 3O); but FTL did not have an independent prognostic
value in GBMs (Table 3).
Association with grade and prognostic impact of microglial score in
astrocytomas
The microglial score for FTH did not differ among the different grades (Fig 4A), whereas the
FTL microglial score was significantly higher in GBMs as compared to DAs and AAs (p<0.05)
(Fig 4B).
In DAs, no significant association between overall survival and FTH was observed (HR 2.0;
95% CI 0.70–5.57; p = 0.20) (score 0–2: n = 8 and score 3–4: n = 15) (Fig 4E). In AAs, high
Fig 3. Association of TfR1, FTH, and FTL tumor cell score with grade and overall survival. TfR1 tumor cell score was found to increase
with grade (A). No increase was observed for FTH (B) and FTL (C). Combining all astrocytomas, high expression of TfR1 was associated with
poor overall survival (D), and low expression of FTH was associated with poor overall survival (E). No association was seen for FTL (F). In the
TfR1 staining, no DAs had a tumor cell score greater than 2 explaining the presence of only one survival curve (G). In the FTH staining, only
one tumor had low tumor cell score (H). No association with overall survival was observed for FTL in DAs (I). In AAs, no association with overall
survival was observed for TfR1 (J) or FTL (L), while low expression of FTH was associated with poor overall survival (K). In GBMs, no
significant association with overall survival was observed for TfR1 (M), FTH (N), or FTL (O). Tumor scores are shown with error bars
representing SEM. *** corresponds to p<0.001. Abbreviations: AA anaplastic astrocytoma, DA diffuse astrocytoma, FTH ferritin heavy chain,
FTL ferritin light chain, GBM glioblastoma, TfR1 transferrin receptor-1.
https://doi.org/10.1371/journal.pone.0182954.g003
Table 3. Multivariate analysis for patients with GBMs (n = 70) with TfR1, FTH, and FTL tumor cell score.
TfR1 FTH FTL
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age 1.0 (0.99–1.04) 0.39 1.0 (0.98–1.03) 0.60 1.0 (0.98–1.03) 0.62
Gender
Female 1.0 1.0 1.0
Male 1.1 (0.66–1.82) 0.72 1.1 (0.66–1.82) 0.83 1.8 (1.09–2.99) 0.02
TCS
0–2 1.0 1.0 1.0
3–4 1.1 (0.70–1.84) 0.62 0.9 (0.54–1.59) 0.78 1.5 (0.90–2.66) 0.12
Abbreviations: CI confidence interval, FTH ferritin heavy chain, FTL ferritin light chain, HR hazard ratio, TCS tumor cell score, TfR1 transferrin receptor-1.
https://doi.org/10.1371/journal.pone.0182954.t003
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microglial score was associated with a better overall survival (HR 0.2; 95% CI 0.04–0.64; p =
0.01) (score 0–2: n = 7 and score 3–4: n = 11) (Fig 4G), while no association with overall survival
was observed for patients with GBM in either in the univariate (HR 1.3; 95% CI 0.82–2.18;
p = 0.24) (score 0–2: n = 31 and score 3–4: n = 39) (Fig 4I) or multivariate analyses (Table 4).
Low FTL microglial score was associated with a better overall survival in all astrocytomas
combined (HR 1.8; 95% CI 1.56–2.79; p = 0.01) (Fig 4D) (score 0–2: n = 33 and score 3–4:
n = 79), and a similar trend was observed in DAs (HR 2.3; 95% CI 0.88–6.81; p = 0.09) (score
0–2: n = 11 and score 3–4: n = 12) (Fig 4F). In AAs, low FTL microglial score was associated
with better outcome (HR 4.9; 95% CI 1.31–17.95; p = 0.02) (Fig 4H) (score 0–2: n = 6 and
score 3–4: n = 12), while no association was found in GBMs (HR 0.7; 95% CI 0.37–1.16; p =
0.15) (score 0–2: n = 16 and score 3–4: n = 54) (Fig 4J). Multivariate analysis of GBMs did not
provide any additional information (Table 4).
Double-immunofluorescence
TfR1 was expressed by CD133-positive tumor cells (Fig 5A–5D) and to a limited degree by
nestin-positive tumor cells (Fig 5E–5H). Tumor cells that co-expressed TfR1 and GFAP were
also identified (Fig 5I–5L). The two ferritin stainings showed similar co-expression patterns.
Few FTH-positive tumor cells co-expressed CD133 (Fig 6A–6D), while no co-expression
between FTH and nestin was observed (Fig 6E–6H). Some IBA-1-positive cells co-expressed
FTH (Fig 6I–6L). A similar co-expression pattern was observed for FTL (Fig 7A–7L).
In silico analyses
To investigate the relation between the iron-related molecules and microglia/macrophages fur-
ther, correlation analyses between IBA-1 and TfR1, FTH, and FTL were performed using the
TCGA dataset. No significant correlation was found between IBA-1 and TfR1 mRNA expres-
sion (rs = -0.05; 95% CI 0.14–0.04; p = 0.24) (Fig 8A), while IBA-1 was positively correlated
Fig 4. Association of FTH and FTL microglial score with grade and overall survival. FTH microglial
score was similar across tumor grades (A), whereas FTL microglial score increased with WHO grade (B).
Combining all astrocytomas, no association with survival was observed for FTH (C), but high FTL microglial
score was associated with poor survival (D). No association with overall survival was seen for FTH (E) or FTL
(F) in DAs. In AAs, high FTH was associated with longer overall survival (G), whereas low FTL microglial
score was associated with longer overall survival (H). In GBMs, no association with overall survival was
observed for FTH (I) or FTL (J). Microglial scores are shown with error bars representing SEM. * corresponds
to p<0.05. Abbreviations: AA anaplastic astrocytoma, DA diffuse astrocytoma, FTH ferritin heavy chain, FTL
ferritin light chain, GBM glioblastoma.
https://doi.org/10.1371/journal.pone.0182954.g004
Table 4. Multivariate analysis for patients with GBMs (n = 70) with FTH and FTL microglial score.
FTH FTL
Variable HR (95% CI) p-value HR (95% CI) p-value
Age 1.0 (0.80–2.18) 0.78 1.0 (0.98–1.03) 0.65
Gender
Female 1.0 1.0
Male 1.0 (0.61–1.68) 0.96 1.8 (1.09–2.99) 0.05
MS
0–2 1.0 1.0
3–4 1.3 (0.80–2.18) 0.27 0.7 (0.40–1.28) 0.26
Abbreviations: CI confidence interval, FTH ferritin heavy chain, FTL ferritin light chain, HR hazard ratio, MS
microglial score
https://doi.org/10.1371/journal.pone.0182954.t004
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with both FTH (rs = 0.41; 95% CI 0.34–0.49; p<0.001) (Fig 8B) and FTL (rs = 0.67; 95% CI
0.61–0.71; p<0.001) (Fig 8C).
Investigating the mRNA expression levels of TfR1, FTH, and FTL in the four different
GBM subtypes, TfR1 levels were found to be significantly lowest in the proneural subtype com-
pared to the classical, mesenchymal, and neural subtypes (p<0.001) (Fig 8D). FTH expression
was significantly higher in the mesenchymal and neural subtype compared to the classical
(p<0.001) and proneural subtypes (p<0.001 and p<0.01, respectively) (Fig 8E), while FTL
expression levels were highest in the mesenchymal subtype (p<0.001 or p<0.01) (Fig 8F).
Investigating the association between iron-related mRNA levels and survival in the different
GBM subtypes showed that TfR1, FTH, and FTL had limited prognostic value in classical
GBMs (p>0.05) (S1A–S1C Fig). In mesenchymal GBMs, only high levels of TfR1 negatively
correlated with overall survival (HR 1.4; 95% CI 1.00–2.01; p = 0.049) (S1D–S1F Fig). In neu-
ral GBMs, overall survival was not associated with TfR1, FTH, or FTL (p>0.05) (S1G–S1I
Fig). In proneural GBMs, high levels of TfR1 were significantly associated with shorter overall
survival (HR 2.3; 95% CI 1.49–3.39; p<0.001) (S1J Fig); while FTH and FTL did not correlate
with survival (p>0.05) (S1K and S1L Fig).
Discussion
In our cohort, TfR1 expression was predominantly seen in GBMs, and high TfR1 expression
was associated with worse prognosis analyzing all astrocytic brain tumors together. High TfR1
Fig 5. TfR1 double-immunofluorescence stainings. Co-expression of TfR1 and CD133 was observed in a number of tumor cells (A-D). Some tumor
cells showed limited co-expression with nestin (E-H). A few tumor cells expressed both TfR1 and GFAP (I-L). Abbreviations: GFAP glial fibrillary acidic
protein, TfR1 transferrin receptor-1. Scale bar: 50 μm.
https://doi.org/10.1371/journal.pone.0182954.g005
Iron-related proteins in astrocytomas
PLOS ONE | https://doi.org/10.1371/journal.pone.0182954 August 24, 2017 12 / 20
expression has also been observed in other cancers [31–34]. Recently, analysis of brain tumor
data sets from Oncomine suggested that high mRNA levels of TfR1 were associated with high
tumor grade. Analyzing the TCGA and the National Cancer Institute REpository for Molecu-
lar BRAin Neoplastic Data (NCI REMBRANDT) datasets, high TfR1 levels were found corre-
late with shorter overall survival in patients with glioma, and similar results were found when
investigating protein expression data from grade II-IV TMAs [20]. In the present study, we
performed a more comprehensive analysis and found no association between TfR1 expression
and survival in the individual astrocytoma grades. This suggests that the prognostic signifi-
cance of the iron-related proteins previously observed in all astrocytomas is related to WHO
grade and does not provide additional prognostic information. We found that cells with tumor
morphology co-expressed TfR1 and GFAP; additionally we observed co-expression of TfR1
and the stem cell-related markers CD133 and nestin, which is consistent with recently reported
data demonstrating that GBM cells co-express TfR1 and the stem cell-related marker SOX2
[20]. Overall, these findings suggest that TfR1 may play a role at different levels of the tumor
cell differentiation hierarchy; however, the association between TfR1 and cellular differentia-
tion needs further investigation.
Almost all astrocytic tumors in our cohort expressed the two ferritin proteins. High FTH
tumor cell expression was associated with a better prognosis in all astrocytomas, and this was
also seen in AAs. In contrast, FTL was not associated with survival, and for both FTH and
FTL no difference was observed among malignancy grades. These results are different from
Fig 6. FTH double-immunofluorescence stainings. Co-expression of FTH and CD133 was observed in a number of tumor cells (A-D). Co-expression
of FTH and nestin was not observed (E-H). Co-expression was often seen for FTH and the microglial/macrophage marker IBA-1 (I-L). Abbreviations:
FTH ferritin heavy chain, IBA-1 ionized calcium-binding adapter molecule 1. Scale bar 50 μm.
https://doi.org/10.1371/journal.pone.0182954.g006
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previous results obtained using TMAs composed of 95 grade II-IV gliomas of oligodendroglial
and astroglial type, where high immunohistochemical scores for FTH and FTL were associated
with shorter overall survival [20]. The discrepancy could be explained by inclusion of grade II
and III oligodendroglial tumors in the TMA cohort, which is in contrast to our cohort contain-
ing only astrocytic tumors thereby reducing the risk of bias in the survival analysis. Focusing
on GBMs and analyzing gene expression data from the TCGA dataset, high levels of FTH1
mRNA and FTL mRNA were previously found to be associated with poor outcome [20]. How-
ever, apparently these findings do not extend to the protein level as no association with sur-
vival was found in our data or in the TMA study [20]. In breast cancer, both high levels of
FTH and FTL have been suggested to be associated with poor outcome [35]. However, in tri-
ple-negative breast cancer, high FTH expression was a favorable prognostic factor if the pro-
tein was present in the cytoplasm [36], thereby adding to the complexity of understanding and
using iron-related proteins as biomarkers. In the context of gliomas, the four different molecu-
lar GBM subtypes may influence survival analysis in GBMs, especially when working with
smaller patient cohorts [37]. To elucidate whether the expression levels of TfR1, FTH, and FTL
differed among the GBM subtypes, we used the TCGA dataset and found that neural and espe-
cially mesenchymal GBMs overall had the highest expression levels of the three iron-related
genes. When investigating the association between the three iron-related genes and overall sur-
vival in the four different GBM subtypes, high mRNA levels of TfR1 significantly correlated
with overall survival, but only in the mesenchymal and proneural subtypes. Thus, accounting
Fig 7. FTL double-immunofluorescence stainings. Co-expression of FTL and CD133 was observed in a number of tumor cells (A-D). Co-expression
of FTL and nestin was not observed (E-H). Co-expression was often seen for FTL and the microglial/macrophage marker IBA-1 (I-L). Abbreviations: FTL
ferritin light chain, IBA-1 ionized calcium-binding adapter molecule 1. Scale bar 50 μm.
https://doi.org/10.1371/journal.pone.0182954.g007
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for GBM subtype in the survival analysis performed on our patient cohort could increase the
prognostic significance of the three iron-related proteins, especially TfR1, although a larger
cohort would be needed to ensure statistical significance.
More recently, a study from Wu et al. showed that FTL was elevated in GBM and silencing
FTL in vitro inhibited the cell proliferation [38]. Gautam et al. found that the plasma levels of
FTL were higher in GBM patients compared to healthy controls; however, this could also
reflect that FTL is a marker for inflammation [39]. Altogether, these studies suggest that FTL
plays a role in glioma biology, but the precise role of FTL needs to be further investigated.
FTH and FTL were expressed by a few CD133-positive cells suggesting that ferritins may
not play a crucial role in the BTIC phenotype. However, in a recent study ferritins were found
to be co-expressed to some extent with SOX2 [20]. In contrast, we did not observe any co-
expression between the ferritins and nestin. This could be due the hierarchy that exists within
the BTIC population as nestin may be expressed primarily by cells committed to the neural
lineage, while CD133 and especially SOX2 may be expressed by more immature cells [40].
However, this possible relation between BTIC and iron-related proteins needs further investi-
gation. Interestingly, we also found co-expression between ferritins and IBA-1, a specific
marker of microglia and macrophages suggesting an important role of microglia/macrophages
in brain tumor iron homeostasis which has also been reported by other groups [41–43].
Reportedly, microglia/macrophages are more prevalent in the mesenchymal subtype of GBM
[44] suggesting that the microglial/macrophage contribution to the iron homeostasis is most
significant in this GBM subtype. In return, iron status was found to influence microglial
release of pro-inflammatory cytokines [45]. We approached the potential microglial contribu-
tion to glioma survival by scoring cells with a morphology resembling microglia/macrophages
Fig 8. In silico analyses. IBA-1 mRNA expression did not correlate with TfR1 mRNA expression (A), but showed positive correlation with both FTH
(B) and FTL (C) mRNA expression levels. TfR1 expression was lowest in proneural GBMs (D), while FTH (E) and FTL (F) levels were highest in
mesenchymal and neural GBMs. Error bars represent SEM. * corresponds to p<0.05, ** p<0.01, and *** corresponds to p<0.001. Abbreviations: CL
classical, FTH ferritin heavy chain, FTL ferritin light chain, GBM glioblastoma, IBA-1 ionized calcium-binding adapter molecule 1, MES mesenchymal,
N neural, PN proneural, TfR1 transferrin receptor-1.
https://doi.org/10.1371/journal.pone.0182954.g008
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in the two immunohistochemical ferritin stainings. We observed that a high microglial score
in the FTL staining was associated with poor prognosis in all grades combined as well as in
AAs. In contrast, low FTH microglial score was associated with poor outcome in AAs. This
observation could be explained by microglial phenotype e.g. polarization of microglia towards
a pro-inflammatory or an anti-inflammatory phenotype thereby potentially influencing
survival. Accordingly, iron-related proteins may play different roles in different cell types
highlighting the complexity of interpreting expression of iron-related proteins and using these
proteins as biomarkers.
Using iron-related proteins as targets may also be challenging. Several drugs targeting TfRs
have been developed and tested in different cancers. In gliomas, phase I and II clinical trials
with the TfR ligand transferrin conjugated to diphtheria toxin have been conducted on pa-
tients with recurrent GBMs showing promising results [46, 47]. However, in a phase III trial
the drug failed mainly due to CNS toxicity [48, 49]. Systematic interrogation of iron flux
recently showed that tumor stem cells require TfR1 and ferritins to propagate and form tumors
in vivo [20] supporting that strategies compromising iron flux could be successful since the
aspect of the tumor stem cells is taken into account. Using whole slides of non-cultured patient
tumor tissue, our results supported this showing that TfR1, FTH, and FTL were co-expressed
to some extent with the stem cell marker CD133, and we furthermore found that TfR1 was ele-
vated in GBMs and associated with short survival in astrocytomas. On the other hand, the
results obtained from survival analyses with FTH and FTL and the identified microglial
expression suggest that iron-flux in gliomas may be dependent of different cell types and cross-
talk between these cell types.
In conclusion, we found that TfR1 tumor cell expression increased with malignancy grade.
No grade-dependent increase was found for the tumor cell expression of FTH and FTL, but the
expression level of FTL by microglia was highest in GBMs. These findings suggest that iron-
related proteins, primarily TfR1 and FTL, may be associated with tumor aggressiveness. The
prognostic values of TfR1, FTH, and FTL in the individual astrocytoma grades were limited.
However, high microglial/macrophage expression of FTL, but not FTH, correlated with shorter
survival in all astrocytomas suggesting that development of future therapeutic strategies com-
promising iron flux should take tumors cells as well as microglia/macrophages into account.
Supporting information
S1 Fig. Association between iron-related mRNA levels and overall survival in the different
GBM subtypes. In the classical GBM subtype, no significant association between overall sur-
vival and TfR1 (A), FTH (B), or FTL (C) was found. In the mesenchymal subtype, high levels
of TfR1 correlated with poor prognosis (D), while no significant correlation was found
between overall survival and FTH (E) or FTL (F). In neural GBMs, TfR1 (G), FTH (H), and
FTL (I) did not correlate with survival. In proneural GBMs, high TfR1 was significantly associ-
ated with shorter overall survival (J). Similar tendency was observed for FTH (K), while no
correlation existed between overall survival and FTL mRNA levels (L).
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transferrin receptor-1.
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